Currently, adrenal corticosteroids (steroids) are used for a wide variety of clinical conditions. Steroids are known to cause many pathologic effects, including chemically induced diabetes, psychological changes, musculoskeletal (including avascular) necrosis, suppression of the adrenals, and significant effects on the eye. Considering the important risk factors involved with the use of these toxic, yet essential medications, pharmacists have a serious responsibility to monitor their use for indications, dosage, interactions, and side effects.
Get full access to this article
View all access options for this article.
References
1.
Facts and Comparisons: St Louis, Lippincott, August 1983, p 122
2.
Anonymous: Drug Information 1988. American Hospital Formulary System. Bethesda, MD, American Society of Hospital Pharmacists, 1988
3.
Flavin DK, Fredrickson PA, Richardson JW: Mayo Clin Proc58:764-766, 1983
4.
Gottlief NL, Riskin WG: Complications of local corticosteroid injections. JAMA243:1547-1548, 1980
5.
Hollander JL: Intrasynovial corticosteroid therapy, in Hollander JL, McCarthy DJ (eds): Arthritis and Allied Conditions (8th ed). Philadelphia, Lea & Febiger, 1972, pp 517-534
6.
Steinbrocker O., et al: Aspiration and Injection Therapy in Musculoskeletal Disorders . New York, Harper & Row, 1972
7.
McCarty DJ: Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide . Arthritis Rheum15: 157-173,1972
8.
Koehler BE, Urowitz MB, Killinger JW: The systemic effects of intra-articular corticosteroid. J Rheumatol1: 117-125,1974
9.
Morgan J., McCarty DJ: Tendon ruptures in patients with systemic lupus erythematosus treated with corticosteroids. Arthritis Rheum17:1033-1036, 1974
10.
Andruew GC, Domonkus AN: Diseases of the Skin. Clinical Dermatology (6th ed). Philadelphia, Saunders, 1971, pp 87-111
11.
Hollander JL , Brown EM, Jessar RA: The effect of triamcinolone on psoriatic arthritis—A two-year study. Arthritis Rheum2:513-525, 1959
12.
Fraser CG, Preuss FS, Bigford WD: Adrenal atrophy and irreversible shock associated with cortisone therapy. JAMA149:1542-1543, 1952
13.
Slaney G., Brooke BN: Postoperative collapse due to adrenal insufficiency following cortisone therapy . Lancet1:1167-1170, 1957
14.
Donald RA: Dexamethasone suppression of the plasma corticosterone response to stress in the rat. J Physiol (Lond)182:603-611, 1966
15.
Treadwell Blj , Savage O., Sever ED: Pituitary-adrenal function during corticosteroid therapy. Lancet1: 355-358, 1963
16.
Ackerman GL , Nolan CM: Adrenocorticoid responsiveness after alternate-day corticosteroid therapy. N Engl J Med278:405-409, 1968
17.
Nichols T., Nugent CH, Tyler FH: Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab25:343-349, 1965
18.
Maberly DJ, Gibson GJ, Butler AG: Recovery of adrenal function after substitution of beclomethasone dipropionate for oral corticosteroids. Br Med J1:778-782, 1973
19.
Livanou T., Ferriman D., James Vht: Recovery of hypothalamopituitary-adrenal function after corticosteroid therapy . Lancet2:856-859, 1967
20.
Christy NP, Wallace EZ, Jailer JW: Comparative effects of prednisone and of cortisone in suppressing the response of the adrenal cortex to exogenous adrenocorticotropin. J Clin Endocrinol Metab16:1059-1074, 1956
21.
Steroid therapy and the adrenals: Lancet2:537-538, 1975
22.
Sampson PA, Brooke BN, Winstone NE: Biochemical confirmation of collapse due to adrenal failure. Lancet1:1377,1961
23.
Sampson PA, Winstone NE, Brooke BE: Adrenal function in surgical patients after steroid therapy. Lancet2:322-325,1962
24.
Jasani MK, Freeman PA, Boyle JA: Studies of the rise in plasma 11-hydroxycorticosteroids (11-OCHS) in corticosteroid-treated patients with rheumatoid arthritis during surgery. Q J Med37:407-421, 1968
25.
Graber AL, Ney RL, Nicholson WE: Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids. J Clin Endocrinol Metab25:11-16, 1965
26.
Byyny RL: Withdrawal from glucocorticoid therapy. N Engl J Med293:30-32, 1976
27.
Cruess RL: Experience with steroid-induced avascular necrosis of the shoulder and etiologic considerations regarding osteonecrosis of the hip. Clin Orthoped130:1978
28.
Amstutz HC, Carey EJ: Skeletal manifestations and treatment of Gaucher's disease. J Bone Joint Surg48A: 670-701,1966
29.
Diggs L., Pulliam HN, King JC: Bone changes in sickle-cell anemia. S Med J50:249-259, 1937
30.
Patterson RJ , Bickel WH, Dahlin DC: Idiopathic avascular necrosis of the head of the femur—A study of 52 cases. J Bone Joint Surg46A:267-282, 1964
31.
McCallum RI, et al: Gout, hyperuricemia and aseptic necrosis of the femoral head , in Idiopathic Ischemic Necrosis of the Femoral Head in Adults . StuttgartThieme Publ, 1971, p133
32.
Solomon L.: Drug induced arthropathy and necrosis of the femoral head. J Bone Joint Surg55B:246-261, 1973
33.
Boettcher WG , Bonfiglio M., Hamilton HH: Non-traumatic necrosis of the femoral head—I. Relation of altered hemostasis to etiology. J Bone Joint Surg52A: 312-321, 1970
34.
Catto M., et al: The etiology of steroid induced avascular necrosis of bone—A laboratory and clinical study. Clinical Orthoped133:178, 1975
